Correlation of Metabolic Syndrome with Clinicopathological Characteristics and Treatment Outcome in Bladder Cancer: A Retrospective Observational Study
MetS & Treatment Outcomes among BC Patients
Vol. 17 No. 1 : 2022 (166-179)
Abstract
The relationship between metabolic syndrome (MetS) with the clinicopathological characteristics, chemotherapy responsiveness and survival outcome in bladder cancer is under-investigated and often conflicting. We retrospectively analysed data of 45 patients who were diagnosed with non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) and received chemotherapy at the University of Malaya Medical Centre (UMMC) between 2010 and 2020. Overall, 24 patients (53.3%) were presented with MetS criteria at the time of diagnosis. Across MetS and its components, no significant association was found with tumour pathological stage, histological grade, and chemotherapy response in our patient population. Interestingly, there was a significant difference in overall survival between patients with and without diabetes (62.47 + 8.32 months and 84.93 + 3.96 months respectively, p=0.045). Although no significant association between MetS with bladder cancer clinicopathological characteristics and treatment outcome was found, intensive care and lifestyle modification should be considered for bladder cancer patients with metabolic disorders.
Keywords :
Diabetes mellitus,
Drug Therapy,
metabolic syndrome,
survival,
Urinary Bladder Neoplasms,
Correspondance Address
Nur Akmarina B.M. Said. Department of Pharmaceutical Life Sciences, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia. Tel: +603-7967 4969 E-mail: nur_akmarina@um.edu.my
References
Arici, S., Geredeli, C., Secmeler, S., Cekin, R., Sakin, A., Cihan, S. 2020. The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy. Curr Probl Cancer 44(1): 100485.
Bahl, M., Ennis, M., Tannock, I.F., Hux, J.E., Pritchard, K.I., Koo, J., Goodwin, P.J. 2005. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res Treat 94(2): 135-44.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424.
Brindisi, M., Fiorillo, M., Frattaruolo, L., Sotgia, F., Lisanti, M., Cappello, A. 2020. Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERRα Pathway. Cells 9: 1819.
Cheng, S., Zheng, Q., Ding, G., Li, G. 2019. Influence of serum total cholesterol, LDL, HDL, and triglyceride on prostate cancer recurrence after radical prostatectomy. Cancer Manag Res 11: 6651-61.
Evers, J., Grotenhuis, A.J., Aben, K.K.H., Kiemeney, L., Vrieling, A. 2020. No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. PLoS One 15(3): e0229384.
Garg, T., Young, A.J., O’Keeffe-Rosetti, M., McMullen, C.K., Nielsen, M.E., Murphy, T.E., Kirchner, H.L. 2020. Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults. Urol Oncol 38(9): 737.e717-737.e723.
Guo, M., Liu, T., Li, P., Wang, T., Zeng, C., Yang, M., Li, G., Han, J., Wu, W., Zhang, R. 2019. Association Between Metabolic Syndrome and Breast Cancer Risk: An Updated Meta-Analysis of Follow-Up Studies. Front Oncol 9: 1290.
Han, F., Wu, G., Zhang, S., Zhang, J., Zhao, Y., Xu, J. 2021. The association of metabolic syndrome and its components with the incidence and survival of colorectal cancer: a systematic review and meta-analysis. Int J Biol Sci 17(2): 487-97.
Huang, W.-L., Huang, K.-H., Huang, C.-Y., Pu, Y.-S., Chang, H.-C., Chow, P.-M. 2020. Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study. BMC Urol 20(1): 117.
Hwang, E.C., Kim, Y.J., Hwang, I.S., Hwang, J.E., Jung, S.I., Kwon, D.D., Park, K., Ryu, S.B. 2011. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 18(11): 769-76.
Jiang, S., Xu, Z.H., Xu, Q.F., Ding, K., Yuan, M.Z., Guan, Y., Zhao, S.T. 2020. Association between Metabolic Syndrome and tumor histologic grade and pathologic stage of bladder cancer. Arch Urol Res 4(1): 085-9.
Kassi, E., Pervanidou, P., Kaltsas, G., Chrousos, G. 2011. Metabolic syndrome: definitions and controversies. BMC Med 9: 48.
Kleeff, J., Costello, E., Jackson, R., Halloran, C., Greenhalf, W., Ghaneh, P., Lamb, R.F., Lerch, M.M., Mayerle, J., Palmer, D., Cox, T., Rawcliffe, C.L., Strobel, O., Büchler, M.W., Neoptolemos, J.P. 2016. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer 115(7): 887-894.
Lega, I.C., Lipscombe, L.L. 2020. Review: Diabetes, Obesity, and Cancer-Pathophysiology and Clinical Implications. Endocr Rev 41(1):
Leiter, A., Doucette, J., Krege, S., Lin, C.C., Hahn, N., Ecke, T., Sonpavde, G., Bamias, A., Oh, W.K., Galsky, M.D. 2016. Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. Bladder Cancer 2(3): 341-9.
Litton, J.K., Gonzalez-Angulo, A.M., Warneke, C.L., Buzdar, A.U., Kau, S.W., Bondy, M., Mahabir, S., Hortobagyi, G.N., Brewster, A.M. 2008. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25): 4072-7.
Nagase, K., Tobu, S., Kusano, S., Takahara, K., Udo, K., Noguchi, M. 2018. The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder. Curr Urol 12(1): 39-42.
Okamura, T., Hashimoto, Y., Hamaguchi, M., Obora, A., Kojima, T., Fukui, M. 2020. Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study. BMC Endocr Disord 20(1): 113.
Ozbek, E., Otunctemur, A., Dursun, M., Koklu, I., Sahin, S., Besiroglu, H., Erkoc, M., Danis, E., Bozkurt, M. 2014. Association between the metabolic syndrome and high tumor grade and stage of primary urothelial cell carcinoma of the bladder. Asian Pac J Cancer Prev 15(3): 1447-51.
Ozbek, E., Otunctemur, A., Dursun, M., Sahin, S., Besiroglu, H., Koklu, I., Erkoc, M., Danis, E., Bozkurt, M. 2014. Diabetes mellitus and HbA1c levels associated with high grade prostate cancer. Asian Pac J Cancer Prev 15(6): 2555-8.
Qu, F., Chen, R., Peng, Y., Ye, Y., Tang, Z., Wang, Y., Zong, B., Yu, H., Liu, S. 2020. Assessment of the predictive role of serum lipid profiles in breast cancer patients receiving neoadjuvant chemotherapy. J Breast Cancer 23(3): 246-58.
Rivel, T., Ramseyer, C., Yesylevskyy, S. 2019. The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin. Sci Rep 9(1): 5627.
Sha, N., Xu, H., Chen, T., Tian, D.W., Xie, W.Q., Xie, L.G., Zhang, Y., Xing, C., Liu, X.T., Shen, Z.H., Wu, Z.L., Hu, H.L., Wu, C.L. 2016. The evaluation of the association between the metabolic syndrome and tumor grade and stage of bladder cancer in a Chinese population. Onco Targets Ther 9: 1175-9.
Tai, Y.S., Chen, C.H., Huang, C.Y., Tai, H.C., Wang, S.M., Pu, Y.S. 2015. Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. Diabetes Metab Res Rev 31(3): 307-14.
Teleka, S., Jochems, S.H.J., Häggström, C., Wood, A.M., Järvholm, B., Orho-Melander, M., Liedberg, F., Stocks, T. 2021. Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three Swedish cohorts. Cancer Med 10(4): 1431-8.
Warner, E.T., Ballman, K.V., Strand, C., Boughey, J.C., Buzdar, A.U., Carey, L.A., Sikov, W.M., Partridge, A.H. 2016. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat 159(1): 109-18.
Xu, Y., Huo, R., Chen, X., Yu, X. 2017. Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore) 96(46): e8588.
Yang, X.Q., Xu, C., Sun, Y., Han, R.F. 2013. Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis. Asian Pac J Cancer Prev 14(4): 2583-9.
Zuniga, K.B., Graff, R.E., Feiger, D.B., Meng, M.V., Porten, S.P., Kenfield, S.A. 2020. Lifestyle and non-muscle invasive bladder cancer recurrence, progression, and mortality: available research and future directions. Bladder Cancer 6(1): 9-23.
